Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

Hypertension

Volumn 41, Issue 5, 2003, Pages 1021-1026

  White, William B ^a   Duprez, Daniel ^b   St Hillaire, Richard ^c   Krause, Scott ^d   Roniker, Barbara ^d   Kuse Hamilton, Janice ^d   Weber, Michael A ^e  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Centre Hospitlier Beauce Etchemin   (Canada)

^d PFIZER INC   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Aldosterone; Calcium antagonists; Hypertension, essential; Pulse pressure

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; AMLODIPINE; CALCIUM ANTAGONIST; CREATININE; EPLERENONE;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD VESSEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EXCRETION; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SYSTOLIC HYPERTENSION; TITRIMETRY; URINARY EXCRETION;

AGED; ALBUMINURIA; AMLODIPINE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CREATININE; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NAUSEA; PULSATILE FLOW; RECEPTORS, ALDOSTERONE; SPIRONOLACTONE; SYSTOLE; TREATMENT OUTCOME;

EID: 0038673178     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000067463.13172.EA     Document Type: Article

References (27)

1. Stamler J, Stamler R, Neaton J. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med. 1993;153:598-615.
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
4. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto, J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
5. Black HR, Kuller LH, O'Rourke MF, Weber MA, Alderman MH, Benetos A, Burnett J, Cohn JN, Franklin SS, Mancia G, Safar M, Zanchetti A. The first report of the systolic and pulse pressure (SYPP) working group. J Hypertens. 1999;17(suppl 5):S3-S14.
6. Smulyan H, Safar ME. The diastolic blood pressure in systolic hypertension. Ann Intern Med. 2000;32:233-237.
7. White WB. Benefits of antihypertensive therapy in older patients with hypertension. Arch Intern Med. 2000;160:149-150.
8. White WB. The systolic pressure versus pulse pressure controversy. Am J Cardiol. 2001;87:1278-1281.
9. Coats AJ. Exciting new drugs on the horizon: eplerenone, a selective aldosterone receptor antagonist. Int J Cardiol. 2001;80:1-4.
10. Delyani JA, Rocha R, Cook CS, Tolbert DS, Levin S, Roniker B. Eplerenone, a selective aldosterone receptor antagonist. Cardiovasc Drug Rev. 2001;19:185-200.
11. Weinberger M, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild to moderate hypertension. Am J Hypertens. 2002;15:709-716.
12. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaithe S, Kleiman JH, Yang YH, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003. In press.
13. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension. 1995;26:485-490.
14. Derhaschnig U, Kittler H, Woisetschlager C, Bur A, Herkner H, Hirschl MM. Microalbuminuria measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertensive patients. Nephrol Dial Tranplant. 2002;17:81-85.
15. White WB. Advances in ambulatory blood pressure monitoring for the evaluation of antihypertensive therapy in research and practice. In: White WB, ed. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Totowa, NJ: Humana Press; 2000:273-298.
16. Asmar R. Arterial Stiffness and Pulse Wave Velocity. Clinical Applications. Paris: Elsevier; 1999:143-159.
17. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19:1371-1376.
18. Weber KT, Brilla CG. Pathologic hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
19. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EAG, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in rat heart. Am J Physiol Heart Circ Physiol. 2002;283: H1802-H1810.
20. Quaschning T, Ruschitzka F, Shaw S, Luscher TF. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension. 2001;37:801-805.
21. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CD. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990;300:297-300.
22. Dell'Omo G, Penno G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis. 2002;40:1-8.
23. Hoelscher D, Bakris G. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol. 1994;23(suppl I):34-38.
24. Chan JCN, Critchley JAHJ, Tomlinson Brian, Chan TYK, Cochram CS. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without noninsulin-dependent diabetes mellitus. Am J Nephrol. 1997;17:72-80.
25. McMahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol. 2001;1:190-196.
26. Blasi ER, Rocha R, Blomme EAG, Rudolph AE, Polly ML, McMahon EG. Aldostereone and salt induces renal inflammation and fibrosis in hypertensive rats. Am J Physiol. 2003. In press.
27. Jeunemaitre X, Charru A, Chatellier G, Degoulet P, Julien J, Plouin PF, Corvol P, Menard J. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for the treatment of essential hypertension. Am J Cardiol. 1998;62:1072-1077.